Director Adam Wingard Returns as Warner Bros. Pictures and Legendary Pictures Explore the Next Chapter in the Massive Monsterverse Franchise
Coming off the global success of 2021’s “Godzilla vs Kong” cameras are now rolling on the latest entry in Warner Bros. Pictures’ and Legendary Pictures’ cinematic Monsterverse. This latest entry follows up the explosive showdown of Godzilla vs. Kong with an all-new cinematic adventure, pitting the almighty Kong and the fearsome Godzilla against a colossal undiscovered threat hidden within our world, challenging their very existence – and our own. The epic new film will delve further into the histories of these Titans, their origins and the mysteries of Skull Island and beyond, while uncovering the mythic battle that helped forge these extraordinary beings and tied them to humankind forever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220825005274/en/
(L-r) Director ADAM WINGARD and REBECCA HALL on the set of Warner Bros. Pictures’ and Legendary Pictures’ action adventure “GODZILLA VS. KONG,” a Warner Bros. Pictures and Legendary Pictures release. Photo by Vince Valitutti
The film, which recently began principal photography, is again being helmed by director Adam Wingard (“You’re Next” “The Guest”) and stars returning cast members Rebecca Hall (“The Night House” “Resurrection”), Brian Tyree Henry (“Bullet Train” “Atlanta”), and Kaylee Hottle (“Godzilla vs. Kong”), who are now joined by newcomers Dan Stevens (“Gaslit” “Legion” “Beauty and the Beast”), Fala Chen (“Irma Vep” “Shang Chi and the Legend of the Ten Rings”), Alex Ferns (“The Batman” “Wrath of Man” “Chernobyl”) and Rachel House (“Hunt for the Wilderpeople” “Thor: Ragnarok” “Foundation”).
Wingard is directing the currently untitled project from a script by Terry Rossio (“Godzilla vs. Kong” the “Pirates of the Caribbean” series), Jeremy Slater (“Moon Knight”) and Simon Barrett (“You’re Next”). The film is being produced by Mary Parent, Alex Garcia, Eric Mcleod, Brian Rogers, Thomas Tull, and Jon Jashni, with executive producers Josh Grode, Adam Wingard, Jay Ashenfelter, Jen Conroy, Kenji Okuhira and Yoshimitsu Banno.
Once again, Wingard is collaborating with director of photography Ben Seresin (“Godzilla vs. Kong” “World War Z”), production designer Tom Hammock (“Godzilla vs. Kong” “X” “The Guest”), editor Josh Schaeffer (“Godzilla vs. Kong” “Molly’s Game”), and composer Tom Holkenborg (“Godzilla vs. Kong” “Mad Max: Fury Road”), who are now joined by costume designer Emily Seresin (“The Invisible Man” “Top of the Lake”), makeup artist Sabrina Wilson (“Captain Marvel” “The Suicide Squad” “The Book of Bobba Fett”), hairstylist Gloria Pasqua Casny (“The Tomorrow War” “Ford vs Ferrari”), and VFX supervisor Alessandro Ongaro (“The Adam Project” “Ghostbusters: Afterlife”).
The film is being shot on location in Queensland, Australia and is slated for a March 15, 2024, worldwide release from Warner Bros. Pictures except in Japan where it will be distributed by Toho Co., Ltd and in mainland China where it will be distributed by Legendary East.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Brie Dorsey – firstname.lastname@example.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: Arlanis Reply Named Salesforce Implementation Partner of the Year and Community Impact Partner of the Year8.12.2022 11:30:00 EET | Press release
Arlanis Reply, the Reply Group company specialized in Salesforce solutions and services, has been recognized with two awards from Salesforce for its outstanding performance as a partner in the categories "Salesforce Implementation Partner of the Year" and "Community Impact Partner of the Year" in Germany, Austria and Switzerland. With these Partner Awards, Salesforce annually honours partner companies that have demonstrated exceptional commitment to consistently delivering high-quality implementations and business outcomes for their clients. The award for the "Salesforce Implementation Partner" was given in recognition of the variety, complexity and number of customer projects with the highest customer satisfaction. As a long-standing Salesforce Consulting Partner, Arlanis Reply convinced the jury with profound expertise and comprehensive knowledge of the entire Salesforce portfolio – as well as high quality in numerous, cross-industry customer projects. The second "Community Impact Pa
ADVA’s new OSA 3350 SePRC™ optical cesium clock breaks records with industry’s longest holdover8.12.2022 11:00:00 EET | Press release
ADVA (FSE: ADV) today launched its latest optical cesium atomic clock solution, providing unprecedented protection for critical network infrastructure systems that rely on synchronization from GNSS. The new OSA 3350 Super ePRC (SePRC™) delivers extensive timing holdover with high-performance stability and lifetime that significantly outperforms any other solution on the market. It offers a vital lifeline to time-as-a-service (TaaS) and GNSS-backup-as-a-service (GBaaS) providers, defense organizations, communication network operators, power utilities and transportation network operators looking to mitigate the risk of jamming and spoofing attacks. As a GBaaS solution, the OSA 3350 SePRC™ provides a backup to satellite-based synchronization, helping prevent severe harm to businesses and society that long GNSS outages can cause. The new device will enable the most robust PNT solution on the market. “Across all nations, our well-being and safety are more dependent than ever on critical net
Record-Breaking Demand for Alternative Residence and Citizenship8.12.2022 10:39:00 EET | Press release
The number of high-net-worth individuals enquiring about investment migration options has more than doubled since the coronavirus was first reported three years ago, with record numbers of wealthy international investors now looking to diversify their residence and citizenship options amid unprecedented global volatility. Henley & Partners has also seen a huge surge in interest and applications from citizens of highly developed countries such as Canada, the UK, and the US compared to pre-pandemic times, with Americans now the top client nationality seeking alternative residence and/or additional citizenship. Henley & Partners CEO Dr. Juerg Steffen says with many economies now in a post-pandemic phase plagued by security, political, and economic risks, wealthy families are revisiting their priorities to ensure that their legacies, wealth, and lifestyles are protected and future-proofed. “For high-net-worth investors, the optionality of living in or conducting business in a country of th
Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events8.12.2022 10:00:00 EET | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today that the primary endpoint was met in the Phase 3 cardiovascular CLEAR (Cholesterol Lowering via Bempedoic acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes Trial, demonstrating statistically significant relative risk reduction in major adverse CV events (MACE-4) in patients treated with 180 mg/day bempedoic acid compared to placebo (with no or very low statin background).1,3 Comprehensive data from the CLEAR Outcomes Trial, led by US-based biotech company Esperion Therapeutics Inc., will be presented at a key medical congress in early 2023 and subsequently submitted to applicable regulatory authorities. The initial findings from the data indicate that bempedoic acid is the first oral, ACL inhibitor known to reduce both LDL-C levels and risk of major adverse CV events.1 The findings are congruent with previous significant evidence and the latest clinical guidelines highlighting that the lower a person’s LDL-C
ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury8.12.2022 09:30:00 EET | Press release
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today reported interim clinical outcomes from the first ten1 people treated to regulate blood pressure with implantable ARC Therapy, ONWARD’s targeted spinal cord stimulation technique. ARC Therapy immediately improved blood pressure levels for all participants; this benefit has been sustained for the duration of the current follow-up period. Participants have also reported improved quality of life, increased energy and vitality, and reduced dizziness. Aaron Phillips, PhD, Associate Professor, Physiology and Pharmacology, Biomedical Engineering, Cardiac Sciences, Clinical Neurosciences, Cumming School of Medicine, University of Calgary, and the Principal Investigator of the HEMO study, said: “Low blood pressure has long been a hidden complication of spinal cord injury that often goes unrecognized and le
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom